WO2008035572A1 - Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant - Google Patents

Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant Download PDF

Info

Publication number
WO2008035572A1
WO2008035572A1 PCT/JP2007/067415 JP2007067415W WO2008035572A1 WO 2008035572 A1 WO2008035572 A1 WO 2008035572A1 JP 2007067415 W JP2007067415 W JP 2007067415W WO 2008035572 A1 WO2008035572 A1 WO 2008035572A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
genus
extract
sagaribana
sample
Prior art date
Application number
PCT/JP2007/067415
Other languages
English (en)
Japanese (ja)
Inventor
Masaki Arashima
Yoko Asano
Hiroko Yoshida
Akira Hatani
Original Assignee
Noevir Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co., Ltd. filed Critical Noevir Co., Ltd.
Publication of WO2008035572A1 publication Critical patent/WO2008035572A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin

Definitions

  • Moisturizers anti-aging agents, whitening agents, anti-inflammatory agents, and antioxidants
  • the present invention relates to a moisturizer, an anti-aging agent, a whitening agent, and an anti-inflammatory agent comprising a naturally-derived component as an active ingredient.
  • the present invention relates to the use of the genus Sagaribana, the genus Botanus, or an extract thereof.
  • the present invention has developed an active ingredient having an excellent moisturizing action, anti-aging action, whitening action, anti-inflammatory action, or anti-oxidation action, and has a moisturizing agent, anti-aging agent, whitening agent, anti-inflammation having those effects. It is an object to provide an agent, an antioxidant, and various compositions. [0005] As a result of studying various components derived from nature, the present inventors have found that moisturizing action, anti-aging action, and whitening, which are superior to the genus Sagaribana or the genus Botanus, whose effects have not been known. The present inventors have found that there are an action, an anti-inflammatory action, and an anti-oxidant action, and have further studied to complete the present invention.
  • a moisturizer an anti-aging agent, a whitening agent comprising one or more plants selected from the genus Sagaribana or the plant of the genus Botanus or an extract thereof as an active ingredient
  • the present invention relates to an anti-inflammatory agent and an antioxidant.
  • composition comprising a genus Sagaribana or a genus Botanus, or an extract thereof.
  • the plant used as the raw material of the present invention is the Sagaribana family that is an evergreen or deciduous tree.
  • the genus Sagaribana or the genus Botanus, or an extract thereof contains an extremely large number of components that cannot be analyzed, and these act collectively to obtain the various effects of the present invention. It is estimated that
  • the plant used as a raw material is not particularly limited as long as it is a plant belonging to the genus Sagaribana or the genus Boletus, but bar ringtonia asiatica may be used because of its relative availability and effectiveness.
  • bar ringtonia asiatica may be used because of its relative availability and effectiveness.
  • any part of the plant belonging to the genus Sagaribana or the genus Botanus may be used, but for easy use, leaves, stems, seeds, etc. may be used.
  • an extract may be obtained using a plurality of parts. You can also use a mixture of two or more extracts extracted with different solvents.
  • the plant may be used as it is, but considering the extraction efficiency, it is preferable to carry out the extraction after processing such as shredding, drying, and grinding.
  • Extraction methods include, for example, a method of extraction by immersing in an arbitrary extraction solvent for a predetermined time in a cooled or heated state at room temperature, a method of extraction using a distillation method such as steam distillation, or a raw plant
  • a distillation method such as steam distillation
  • the pressing method include pressing to obtain an extract. Any of these methods can be used alone or in combination of two or more.
  • extraction can be performed using a supercritical fluid or a subcritical fluid.
  • the mixture may be stirred or homogenized in an extraction solvent. It is also possible to extract under a caloric pressure using an autoclave.
  • the extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent.
  • the extraction time varies depending on the type of extraction solvent and the extraction temperature, but it is appropriate to set it for about 1 hour to 14 days.
  • the ratio of the plant and the solvent during the extraction is not particularly limited, but is preferably 0.5 to 5 times the solvent for the plant 1; Preferably 100 times by mass.
  • Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin; ethyl ether, propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate, and the like; ketones such as acetone, ethylmethylol ketone, and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, water, carbon dioxide, ethylene, propylene One or more supercritical liquids and subcritical liquids such as hydrogen, ethanol, methanol, and ammonia may be used.
  • the above-mentioned solvent extract of the genus Sagaribana or the genus Botanus can be used as it is. It may be used after aging for a certain period of time, or the concentrated and dried product may be used as water or polar. It can also be dissolved in a solvent and used. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization, desalting, etc., or fractionation treatment by column chromatography etc., as long as these physiological effects are not impaired.
  • the above-mentioned extract of Sagaribana plant or Botanus genus plant or its treated product and fractionated product can be freeze-dried after each treatment and fractionation and dissolved in a solvent at the time of use. It can also be used by being encapsulated in vesicles such as ribosomes or microcapsules.
  • the plant of the genus Sagaribana or the genus Botanus, or an extract thereof has an excellent moisturizing action, anti-aging action, whitening action, anti-inflammatory action, and anti-oxidation action, and is a moisturizing agent, anti-aging agent, whitening agent. It can be preferably used as an anti-inflammatory agent or an antioxidant.
  • Each of these agents is not limited at all in terms of its form and the presence or absence of other ingredients, as long as it contains a sorghum plant or a genus genus plant, or an extract thereof as an active ingredient.
  • any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use etc., and the vehicle (excipient), solvent, Other general additives (antioxidants, colorants, dispersants, etc.) can optionally be included.
  • the amount of the active ingredient in each agent, the plant of the genus Sagaribana, the plant of the genus Botanus, or the extract thereof can be adjusted according to the type of agent, the purpose of use, etc. , based on the total amount, 0.1 in terms of solid content 00001 ⁇ ; 100 wt% is laid preferred, more preferably 0.00; is ⁇ 50 mass 0/0!.
  • a moisturizing agent containing a plant belonging to the genus Sagaribana or Botanus spp. Or an extract thereof as an active ingredient exhibits an excellent moisturizing action on the skin and hair, and has a particularly high moisturizing effect on the skin.
  • An anti-aging agent comprising a plant of the genus Sagaribana or Botanus genus or an extract thereof as an active ingredient has an excellent cell activation effect, collagen production activity, and aromatase activity. Has an accelerating action and exhibits an excellent effect in preventing and improving aging symptoms.
  • Aromatase is an enzyme that works when producing estrogen. If the production of estrogen is promoted by promoting aromatase activity, the skin-beautifying effect of female hormones can be expected to have an anti-aging effect.
  • a whitening agent containing a plant of the genus Sagaribana or Botanus, or an extract thereof, as an active ingredient is effective in improving pigmentation symptoms such as stains and buckwheat, particularly inhibiting tyrosinase activity and suppressing melanin production. Excellent effect on
  • An anti-inflammatory agent comprising a genus Sagaribana or a genus Botanus or an extract thereof as an active ingredient has an excellent hyaluronidase inhibitory effect and suppresses skin inflammation and exhibits an excellent anti-inflammatory action.
  • Antioxidants containing Sagaribana plants or genus plants, or extracts thereof, as active ingredients have excellent free radical scavenging effects and superoxide anion scavenging effects, such as photoaging of the skin. Prevents and exhibits an excellent antioxidant effect.
  • each of these agents can be used for hair and the like as well as applied externally to the skin, and can be applied to various compositions such as an external composition and an oral composition.
  • the composition for external use is not limited to any one category such as cosmetics, external preparations for skin, quasi-drugs, external medicines, etc., but any combination for external use on skin or hair. Means an adult.
  • oral composition means any composition that can be taken orally, regardless of the type of drug, food, beverage, etc.
  • the dosage form of the composition for external use is arbitrary, and can be provided, for example, as a solubilization system such as lotion, a dispersion system such as calamine mouth lotion, or an emulsification system such as cream or emulsion.
  • a solubilization system such as lotion
  • a dispersion system such as calamine mouth lotion
  • an emulsification system such as cream or emulsion.
  • it can be provided in various dosage forms such as aerosol forms, ointments, and poultices filled with propellants.
  • various cosmetics such as emulsions, creams, lotions, lotions, packs, cosmetic liquids, cleaning agents, lipsticks, makeup cosmetics, foundations, etc .; liquids, ointments, powders, granules, aerosols, patching agents
  • examples include various forms of quasi-drugs such as cataplasms and cataplasms for external use.
  • the form of the oral composition is also arbitrary, and is in a liquid form such as a liquid, syrup, or extract, or a solid preparation such as a granule, tablet, powder, capsule, or glaze, or a jelly, It can be processed and used in various forms such as gummi and gum, and is not particularly limited.
  • Specific examples include general foods including beverages, health foods (supplements), functional foods, nutritional supplements, oral medicines, and quasi drugs.
  • a topical skin preparation including, for example, cosmetics, topical medicines, quasi drugs, etc. Prevents various skin symptoms such as reduced skin elasticity, spots, dullness, dryness, fine lines, etc.Preparation of an external composition that exhibits an excellent effect for improvement, and as a skin moisturizing or whitening skin external preparation Can be used.
  • it is preferably used as a skin external preparation for improving aging prevention, which contains a plant belonging to the genus Sagaribana or the genus Botanus, or an extract thereof.
  • Sagaribana or Hoganae plants, or extracts thereof are used for beauty and health maintenance such as whitening, health foods (supplements), quasi-drugs, functional products. It can also be used for foods.
  • compositions for external use or oral use include, for example, sagaribana plants, or Astragalus plants, or extracts thereof, as well as normal skin cosmetics, hair, if necessary.
  • Such components include water, oils (oil-based ingredients), alcohols, excipients, binders, extenders, disintegrants, corrigents, dyes, colorants, emulsifiers, solubilizers, dispersants, gelling.
  • plasticizer plasticizer
  • cleaning agent UV absorber
  • thickener thickener
  • pH adjuster buffer
  • surfactant lubricant
  • chelating agent drug (medicinal ingredient)
  • fragrance resin
  • coating agent antibacterial
  • antibacterial examples include glazes, preservatives, preservatives, antioxidants, and pH adjusters.
  • the dosage form of food is arbitrary, and can be provided in various dosage forms such as powders, granules, capsules, liquids, etc.
  • other moisturizers, anti-aging agents, whitening agents, anti-inflammatory agents, or antioxidants can be used in combination as long as the effects of the present invention are not impaired.
  • the blending amount of the genus Sagaribana or the genus Botanus in the composition for external use or the composition for oral use, or the extract thereof is adjusted according to the kind of composition, the purpose of use, etc. in view of the force effect and stability it can, based on the total amount, preferably from 0. 00001- 50.0 mass 0/0 power Mashigu in terms of solid content ⁇ is 0. 0001- 25.0 mass 0/0. Further, 0.1 0001 ⁇ ; 10 mass 0/0 Ca, more preferably 0.000; a ⁇ 5 mass 0/0, more preferably 0. 00;! A ⁇ 5 wt%, more preferably Is in the range of 0.0;! To 5 mass%, particularly preferably 0;
  • the leaf of Covanno reed or Astragalus was dried and pulverized, 50% ethanol by mass of 20 times the mass of the sample was added, and the mixture was extracted with stirring at room temperature for 2 hours.
  • the obtained extract was filtered to remove insoluble matters, concentrated under reduced pressure, and then freeze-dried to obtain each extract of Copano reed or Hogan.
  • the dermal fibroblast activation action was evaluated as follows.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urchin fetal serum
  • the medium was replaced with a medium containing 400 ⁇ g / ml of 3- (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide (MTT reagent) and cultured for about 2 hours. . Then, the formazan produced by the opening of the tetrazolium ring was extracted with 2 propanol, and the absorbance at 55 Onm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • MTT reagent 3- (4,5 dimethyl 2 thiazolyl) 2,5 diphenyltetrazolium bromide
  • the epidermal cell activation effect was evaluated as follows.
  • Human epidermal non-keratinized cells were seeded in a 96-well microphone mouth plate so that the number of cells was 2.0 ⁇ 10 4 per wellore.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urchin fetal serum (FBS). After culturing for 24 hours, the sample culture medium was adjusted to the sample concentration shown in Table 2 with 5 mass ° / ⁇ 8 S-added DMEM medium, and further cultured for 24 hours.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urchin fetal serum
  • the MTT reagent was replaced with a medium containing lOO ⁇ g / ml and cultured for about 2 hours. Subsequently, fonolemazan produced by the opening of the tetrazolium ring was extracted with 2 propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • the dermal fibroblast collagen production action was evaluated as follows.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the amount of protein was measured by BIER Protein Assay Kit manufactured by PIERCE, and the amount of type I and type III collagen produced per unit protein was determined.
  • Table 3 shows the relative values when the amount of collagen production of type I and type III is 100.
  • the epidermal cell collagen production action was evaluated as follows.
  • Non-keratinized human epidermis cells were seeded in a 96-well microphone mouth plate so that there were 2.0 ⁇ 10 4 cells per well.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS). After culturing for 24 hours, the sample was replaced with a Sampnore culture solution adjusted to each sample concentration shown in Table 4 with a DMEM medium containing 5 mass ° / ( ⁇ 8 S, and further cultured for 5 days.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the protein amount is measured by PIERCE BCA Protein Assay Kit The amount of type IV collagen produced per unit amount was determined.
  • results obtained are the types per unit protein amount in the control with no sample added.
  • Table 4 shows the relative values when the amount of IV collagen produced is 100.
  • the aromatase activity promoting action was evaluated as follows.
  • NADP +, MgCl, Darco was added to 4 ⁇ 1 of the sample solution prepared for each sample concentration shown in Table 5.
  • Fluorescence measurement was performed at an excitation wavelength of 409 nm and an emission wavelength of 530 nm. Since 7-methoxy-4-trifluoromethylcoumarin is decomposed by CYP19 and 7-hydroxy-4-trifluoromethylcoumarin is produced to produce fluorescence, the ability to promote aromatase activity was quantified by fluorescence measurement.
  • results obtained are based on the aromatase activity promoting effect in the control without addition of the sample.
  • Table 5 shows the relative values when 100 is assumed.
  • the epidermal melanocyte tyrosinase activity inhibitory action was evaluated as follows.
  • the hyaluronidase inhibitory action was evaluated as follows.
  • hyaluronic acid potassium salt derived from human umbilical cord
  • 0.1 M phosphate buffer ⁇ 7.0
  • a commercially available hyaluronidase derived from urchin testis
  • 0.1 M phosphate buffer pH 7.0
  • p-D ABA p-dimethylaminobenzaldehyde
  • p-D ABA p-dimethylaminobenzaldehyde
  • Hyaluronidase inhibitory action is defined by the following equation.
  • the extinction rate of DPPH radical was calculated from the following equation, where (A) was the force when the sample was added, and (A) the absorbance when the sample was added, and (B) the absorbance when the sample was added.
  • Radical scavenging rate ⁇ 1 (B) / (A) ⁇ X 100
  • SOD-like activity was evaluated as follows.
  • Cobanno reed extract (Leaf) (Extraction method 1) 5.0 Manufacturing method: Mix the water phase components of (1) to 1 ⁇ 2) and dissolve at 75 ° C with heating. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Start cooling after emulsification and add (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
  • Copano reed extract (Leaf) (Extraction method 1) 6.0 Production method: Heat-dissolve the oil phase components of (1) to (4) at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and mixed with the oil phase components uniformly. Start cooling, add (8) at 40 ° C, and mix uniformly.
  • Cobannoashi extract (leaves) (Extraction method 1) 5.0 Manufacturing method: Mix the oil phase components of (1) to (4) and dissolve at 75 ° C with heating. On the other hand, the aqueous phase components (5) to (7) are mixed, dissolved by heating at 75 ° C, and the pigments (8) to (10) are added thereto and dispersed uniformly with a homomixer. The oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C, and evenly To mix.
  • Cobanno reed extract (Leaf) (Extraction method 1) 5.0 Manufacturing method: Mix the oil phase components of (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the water phase components (7) to (10) are mixed, dissolved by heating at 75 ° C, and the pigments (11) to (15) are added to this and dispersed uniformly with a homomixer. Add oil phase ingredients and emulsify. Cooling is started after emulsification, and components (16) and (17) are added sequentially at 40 ° C and mixed uniformly.
  • Table 11 shows the number of panelists that obtained each evaluation.
  • a moisturizer an anti-aging agent, a whitening agent, an anti-flame having an excellent effect by using a plant belonging to the genus Sagaribana or Botanus, or an extract thereof as an active ingredient.
  • anti-oxidants can be provided.
  • compositions that exhibit excellent effects in preventing and improving various skin symptoms such as skin firmness or skin elasticity reduction, spots, dullness, dryness, and fine wrinkles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)

Abstract

L'invention concerne un agent hydratant, un agent anti-vieillissement, un agent blanchissant la peau et un agent anti-inflammatoire, chacun d'eux comprenant une plante appartenant au genre Barringtonia ou Couroupita ou un extrait de celle-ci comme ingrédient actif. L'invention concerne également une composition comprenant une plante appartenant au genre Barringtonia or Couroupita ou un extrait de celle-ci.
PCT/JP2007/067415 2006-09-19 2007-09-06 Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant WO2008035572A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006253556A JP5025201B2 (ja) 2006-09-19 2006-09-19 保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤
JP2006-253556 2006-09-19

Publications (1)

Publication Number Publication Date
WO2008035572A1 true WO2008035572A1 (fr) 2008-03-27

Family

ID=39200399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/067415 WO2008035572A1 (fr) 2006-09-19 2007-09-06 Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant

Country Status (2)

Country Link
JP (1) JP5025201B2 (fr)
WO (1) WO2008035572A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119852A1 (fr) * 2007-03-30 2008-10-09 Caroi'line Cosmética, S.L. Extrait des feuilles de couroupita guianensis, procédé d'obtention et utilisation cosmétique de cet extrait en tant qu'antioxydant/antiradicalaire/filtre uv

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195925A1 (en) * 2011-11-03 2013-08-01 Vaskin, Llc Anti aging application and method for treating aging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757390A1 (fr) * 1996-12-20 1998-06-26 Dior Christian Parfums Utilisation d'un extrait de la plante barringtonia, dans les domaines cosmetique et pharmaceutique, notamment dermatologique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2756390B1 (fr) * 1996-11-22 2002-11-15 Mesura Ets Appareil de regulation automatique de pression de gaz

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757390A1 (fr) * 1996-12-20 1998-06-26 Dior Christian Parfums Utilisation d'un extrait de la plante barringtonia, dans les domaines cosmetique et pharmaceutique, notamment dermatologique

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] GEETHA M. ET AL.: "Analgesic and anti-inflammatory activity of Couroupita guianensis Aubl", XP003021833, Database accession no. (2004149121) *
JOURNAL OF NATURAL REMEDIES, vol. 4, no. 1, 2004, pages 52 - 55 *
KHAN S. ET AL.: "Antibacterial activity of Barringtonia racemosa", FITOTERAPIA, vol. 42, no. 2, 2001, pages 162 - 164, XP003021835 *
MCCLATCHEY W.: "THE ETHNOPHARMACOPOEIA OF ROTUMA", ETHNOPHARMACOL., vol. 50, no. 3, 1996, pages 147 - 156, XP003021834 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119852A1 (fr) * 2007-03-30 2008-10-09 Caroi'line Cosmética, S.L. Extrait des feuilles de couroupita guianensis, procédé d'obtention et utilisation cosmétique de cet extrait en tant qu'antioxydant/antiradicalaire/filtre uv

Also Published As

Publication number Publication date
JP5025201B2 (ja) 2012-09-12
JP2008074730A (ja) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2008029877A1 (fr) agent anti-vieillissement, agent de blanchiment cutané, agent antioxydant et agent anti-inflammatoire
JP5557414B2 (ja) 保湿剤、細胞賦活剤、及び美白剤
JP2010150207A (ja) 保湿剤、抗老化剤、抗酸化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
JP2008303147A (ja) 皮膚外用剤
JP5306605B2 (ja) 皮膚外用剤
JP5014343B2 (ja) ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤
JP4201091B1 (ja) 保湿剤、抗老化剤、抗酸化剤及び皮膚外用剤
JP5465037B2 (ja) 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物
WO2008035572A1 (fr) Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant
JP5247548B2 (ja) 保湿剤、抗老化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤
JP2008303180A (ja) 美白剤、皮膚外用剤及び機能性経口組成物
JP4748962B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4970442B2 (ja) 美白剤
JP4931452B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4050727B2 (ja) 保湿剤、細胞賦活剤、美白剤、抗酸化剤、及び皮膚外用剤
JP5388555B2 (ja) 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、機能性経口組成物
JP5656348B2 (ja) 保湿剤、抗老化剤、抗酸化剤、免疫賦活剤、美白剤、及び皮膚外用剤、機能性経口組成物
JP5550929B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、皮膚外用剤及び機能性経口組成物
JP5202180B2 (ja) 保湿剤、免疫賦活剤、抗老化剤、美白剤、抗酸化剤、痩身剤、皮膚外用剤及び機能性経口組成物
JP5265489B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
JP4936754B2 (ja) 保湿剤、細胞賦活剤、及びコラゲナーゼ阻害剤
WO2008029879A1 (fr) agent HYDRATANT, ACTIVATEUR cellulaire et antioxydant
JP4869638B2 (ja) 細胞賦活剤、美白剤、抗酸化剤、アミラーゼ阻害剤、及び保湿剤
JP4166790B2 (ja) 保湿剤、ａｔｐ産生促進剤、美白剤、抗酸化剤、中性脂肪蓄積抑制剤、及びコラーゲン産生促進剤
JP5610846B2 (ja) 抗老化剤、抗酸化剤、抗炎症剤、美白剤、保湿剤、皮膚外用剤および機能性経口組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07806856

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07806856

Country of ref document: EP

Kind code of ref document: A1